Press Release Biocartis NV: Biocartis announces new data on early CAR-T vector load assessment with Idylla™ presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring
February 14, 2025 03:30 ET
|
Biocartis NV
PRESS RELEASE - 14/02/2025, 09:30 CET Biocartis announces new data on early CAR-T vector load assessment with Idylla™ presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring ...
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
February 11, 2025 08:45 ET
|
AIM ImmunoTech Inc.
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod)...
Survivor Healthcare Joins Together for Supportive Cancer Care
February 11, 2025 08:08 ET
|
Survivor Healthcare
Survivor Healthcare joins Together for Supportive Cancer Care to expand access to early supportive cancer care through digital health innovation.
EvolveImmune Appoints Kristen M. Hege, M.D. to Its Board of Directors
February 11, 2025 08:00 ET
|
EvolveImmune Therapeutics
BRANFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immunotherapy company developing first-in-category, multifunctional T Cell engager biotherapeutics to address unmet...
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 11, 2025 07:00 ET
|
Arvinas Inc.
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in...
University Cancer & Blood Center’s Dr. Ashley Ray receives oncoplastic breast surgery certification
February 06, 2025 11:48 ET
|
University, Cancer and Blood Center
University Cancer & Blood Center (UCBC), based in Athens, Georgia, announces that Dr. Ashley Ray now has her certification in oncoplastic breast surgery.
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
February 06, 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response...
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
February 06, 2025 08:00 ET
|
Allarity Therapeutics, Inc.
Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a...
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
February 06, 2025 07:00 ET
|
Immuneering Corporation
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Nuclear Medicine Market Size to Accumulate Around USD 38.8 Billion by 2032, Growing at a 15% CAGR - SNS Insider
February 05, 2025 09:30 ET
|
SNS Insider pvt ltd
Pune, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuclear Medicine Market Size & Growth Analysis: According to SNS Insider, The Global Nuclear Medicine Market size was valued at USD 11.1 billion in 2023...